Asthma

CD4+ tissue-resident memory T cells may trigger severe, and potentially fatal, asthma attacks in men aged 40 years and older.

More individuals who used e-cigarettes have reported pulmonary diseases compared with those who never smoked, including asthma.

Investigators created a model to predict asthma exacerbations that can be integrated in WhatsApp chatbot and relies on self-reported data.

Many patients would like more education about managing their asthma, which can help to reduce the overuse of short-acting beta-2 agonists.

Investigators hope that continued research and addressing disparities can improve equitable access to asthma treatments for all pediatric patients.

A workgroup of asthma treatment experts introduced 6 new criteria that those diagnosed with asthma must meet to be in remission.

A patient with lung adenocarcinoma who was treated with an immune checkpoint inhibitor developed symptoms related to asthma and breathing obstruction.

Pediatric and maternal respiratory syncytial virus (RSV) vaccines are being studied to reduce the burden of RSV, and more research is needed to understand whether this can reduce wheeze and asthma.

The upcoming study seeks to analyze whether immature lungs in infants infected with respiratory syncytial virus increases the likelihood of developing asthma later in life.

The study authors said that, to their knowledge, this will be the first systematic review focusing on the effects of cognitive interventions for those with chronic respiratory diseases.

The impact of smoke caused by Canadian wildfires raises concern for wildfire–related fine particles.

OTC nicotine replacement products can come in a transdermal patch, nicotine gum, or lozenges.

This treatment approach helps reduce symptoms and future exacerbations triggered by dust mites, pet dander, pollen.

Balancing clinicians’ priorities with the needs of patients and their families is crucial to ensure access and adherence to medications.

Teach pharmacy staff members to know and address the roadblocks, keep up with changing guidelines.

But analysis does suggest a small increase in risk for individuals who used cigarettes and electronic nicotine delivery systems together.

Data show that dose-response relationships and long-term safety of ICS in people with chronic obstructive pulmonary disease are unclear and require further investigation.

The new findings, which include updated data, contradict results of a previous analysis by the same investigators.

Data show pharmacist-led clinical consultations can improve patient adherence to medication plans.

In a clinical trial program, 92% of health care providers, patients, and caregivers were able to successfully administer tezepelumab-ekko both in the clinic and at home for severe asthma.

The drug combination can significantly improve lung function and reduce severe asthma exacerbations.

FDA committee voted that trial data do not support the benefits outweighing the risks in patients aged 12 to 17 years and children aged 4 to 11 years for the use of albuterol/budesonide in the treatment of asthma.

Inhibiting the calcium release-activated calcium channel found to be an effective approach to limit allergic asthma without affecting the body’s defenses against influenza.

Dupilumab is used as a maintenance therapy when added to other asthma medications.

Aobbiy is a lung expansion and mucus relief device that aids in mucus removal to help clear the airway.

FDA approved dexamethasone tablets USP 1.5mg, 4mg and 6mg, providing a new generic alternative to the steroid Decadron.

Subcutaneous immunotherapy-induced antibodies may serve as a potential allergen-targeted biologics candidate for the treatment of allergic asthma.

ProAir Digihaler Inhalation Powder is indicated for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Study findings provide evidence that preventative antibiotics improve health outcomes for babies and mothers, investigator say.

The study marks the first time an albuterol/budesonide fixed-dose combination rescue medication has reduced severe exacerbations, the company said.